Artiva Biotherapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

ARTV$4.06-3.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,
	2025	2024	2025	2024
License and development support revenue (including related party amounts of $0, $0, $0 and $251, respectively)	$—	$—	$—	$251
Operating expenses:
Research and development (including related party amounts of $13, $1,342, $63 and $2,802, respectively)	17,633	13,524	52,546	37,011
General and administrative	5,264	4,811	15,332	12,255
Total operating expenses	22,897	18,335	67,878	49,266
Loss from operations	(22,897)	(18,335)	(67,878)	(49,015)
Other income (expense), net:
Interest income	1,372	1,846	4,797	3,172
Change in fair value of SAFEs (including related party amounts of $0, $799, $0 and $2,911, respectively)	—	(977)	—	(3,597)
Other (expense) income, net	(3)	(6)	(12)	162
Total other income (expense), net	1,369	863	4,785	(263)
Net loss	$(21,528)	$(17,472)	$(63,093)	$(49,278)
Net loss per share, basic and diluted	$(0.88)	$(0.92)	$(2.59)	$(7.16)
Weighted-average common shares outstanding, basic and diluted	24,481,722	18,896,829	24,401,353	6,883,271
Comprehensive loss:
Net loss	$(21,528)	$(17,472)	$(63,093)	$(49,278)
Other comprehensive income:
Unrealized gain on investments, net	85	217	216	30
Comprehensive loss	$(21,443)	$(17,255)	$(62,877)	$(49,248)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.